FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Publications
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕
Published by Resulted on March 10, 2022
Categories
for2240 | Prof. Ilva Rupenthal
  • DateMarch 10, 2022
  • Executive Board
  • Research Groups
  • Central Projects
  • Associated projects
  • Alumni

Curriculum Vitae

Prof. Ilva Rupenthal

for2240 | Prof. Ilva Rupenthal

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)

Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)

Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)

Contact

Claudia Bock
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
claudia.bock@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck